[1] PARYZHAK SIA, IAKUBETS' O I, VOROBETS Z D. Markers and regulatory mechanisms in ovarian carcinoma[J]. Ukr Biochem J, 2014,86(4):36-50. [2] LU K H. Screening for ovarian cancer in asymptomatic women[J]. JAMA, 2018, 319(6):557-558. [3] KUMARI S. Serum biomarker based algorithms in diagnosis of ovarian cancer:A review[J]. Indian J Clin Biochem, 2018,33(4):382-386. [4] MOORE R G, MCMEEIN D S, BROWN A K, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass[J]. Gynecol Oncol, 2009,112(1):40-46. [5] LYCKE M, KRISTJANSDOTTIR B, SUNDFELDT K. A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index[J]. Gynecol Oncol, 2018,151(1):159-165. [6] CHAN K K, CHEN C A, NAM J H, et al. The use of HE4 in the prediction of ovarian cancer in Asian women with a pelvic mass[J]. Gynecol Oncol, 2013,128(2):239-244. [7] ROMAGNOLO C, LEON A E, FABRICIO A S C, et al. HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass:An Italian multicenter study[J]. Gynecol Oncol, 2016,141(2):303-311. [8] JEONG T D, CHO E J, KO D H, et al. A new strategy for calculating the risk of ovarian malignancy algorithm(ROMA)[J]. Clin Chem Lab Med, 2017,55(8):1209-1214. [9] SANDRI M T, BOTTARI F, FRANCHI D, et al. Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass:correlation with pathological outcome[J]. Gynecol Oncol, 2013,128(2):233-238. [10] CRADIC K W, LASHO M A, ALGECIRAS-SCHIMNICH A. Validation of the cut-points recommended for ROMA using the roche elecsys CA125 and HE4 assays[J]. Ann Clin Lab Sci, 2018,48(1):90-93. [11] HENDERSON J T, WEBBER E M, SAWAYA G F. Screening for ovarian cancer:updated evidence report and systematic review for the US preventive services task force[J]. JAMA, 2018,319(6):595-606. [12] IONESCU C A, MATEI A, NAVOLAN D, et al. Correlation of ultrasound features and the Risk of Ovarian Malignancy Algorithm score for different histopathological subtypes of benign adnexal masses[J]. Medicine (Baltimore), 2018,97(31):e11762. [13] YANG W L, ZHEN L, ROBERT C B. The role of biomarkers in the management of epithelial ovarian cancer[J]. Expert Rev Mol Diagn, 2017,17(6):577-591. [14] WEI S, LI H, ZHANG B. The diagnostic value of serum HE4 and CA-125 and ROMA index in ovarian cancer[J]. Biomed Rep, 2016,5(1):41-44. [15] MOORE R G, MILLER M C, DISILVESTRO P, et al. Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass[J]. Obstet Gynecol, 2011,118(2 Pt 1):280-288. [16] LIN J, QIN J, SANGVATANAKUL V. Human epididymis protein 4 for differential diagnosis between benign gynecologic disease and ovarian cancer:a systematic review and meta-analysis[J]. Eur J Obstet Gynecol Reprod Biol, 2013, 167(1):81-85. [17] ANTON C, CARVALHO F M, OLIVEIRA E I,et al. A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses[J]. Clinics(Sao Paulo), 2012,67(5):437-441. [18] SHEN F X, LU S M, PENG Y B, et al. Performance of ROMA based on Architect CA125Ⅱ and HE4 values in Chinese women presenting with a pelvic mass:A multicenter prospective study[J]. Clin Chim Acta, 2017,471:119-125. [19] BANDIERA E, ROMANI C, SPECCHIA C, et al. Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management[J]. Cancer Epidemiol Biomarkers Prev, 2011, 20(12):2496-2506. [20] DAYYANI F, UHLIG S, COLSON B, et al. Diagnostic performance of risk of ovarian malignancy algorithm against CA125 and HE4 in connection with ovarian cancer:A meta-analysis[J]. Int J Gynecol Cancer, 2016,26(9):1586-1593. [21] 冯艾,张琳,陈艳炯.不同绝经状态女性血清HE4、CA125和ROMA指数在卵巢癌诊断中的意义[J].西安交通大学学报:医学版,2018,39(1):78-83. [22] MOLINA R,ESCUDERO J M,AUGÉ J M,et al. HE4:a novel tumour marker for ovarian cancer:comparison with CA125 and ROMA algorithm in patients with gynaecological diseases[J].Tumour Biol,2011,32(6):1087-1095. |